Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.61 |
| ▸ | CCND1 | P24385 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13157277 | 0.85 | CDK4 (0.57) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL18405592 | 0.85 | CDK4 (0.57) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL24109782 | 0.82 | HTR2A (0.56) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL418136 | 0.81 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL12605582 | 0.80 | CDK4 (0.61) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL4596619 | 0.79 | KMT2A (0.58) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL1629560 | 0.77 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL29433250 | 0.77 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL11366447 | 0.76 | CDK4 (1.00) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL24143572 | 0.76 | HTR2C (0.57) | HTR2AHTR2CCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-11560370-B1 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210230183-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-29 | — | — | US | disclosed |
| US-20190119295-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-25 | — | — | US | disclosed |
| US-9175038-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230183-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CDK4 156/4885CCND1 1591/4885HTR2A 4714/4885 |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK2, PLK4 | CDK4 371/4885CCND1 760/4885HTR2A 4228/4885 |
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | CDK4 2514/4885CCND1 2772/4885HTR2A 3583/4885 |
| US-11560370-B1 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | HCCS, HAVCR2, MAVS | CDK4 503/4885CCND1 2631/4885HTR2A 3788/4885 |
| US-20190119295-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CDK4 156/4885CCND1 1591/4885HTR2A 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.